Department of Dermatovenereology, Charles University Third Faculty of Medicine, Prague, Czech Republic.
J Eur Acad Dermatol Venereol. 2017 Sep;31 Suppl 5:13-17. doi: 10.1111/jdv.14375.
Actinic keratosis (AK) is a characteristic skin lesion on skin areas of subjects with mainly phototype I and phototype II, or with specific genetic factors and who are exposed to prolonged ultraviolet radiation. AK may be considered a precursor of in situ squamous cell carcinoma (SCC), a type of non-melanoma skin cancer (NMSC). However, it is still not possible to predict which AK lesions will develop into SCC. Early treatment of AK is therefore recommended. Despite the increasing number of patients with AK developing into SCC, to date, there is still no clear suggestion of therapeutic strategy for AK. Current treatment consists of a multitude of topical lesion-directed or field-directed therapies or a combination of both. Recently, orally administered nicotinamide has shown to significantly reduce rates of new NMSC and AK in high-risk patients. This study aims to provide an update on the most relevant information about AK and to provide an insight into current and new treatment options.
光化性角化病（AK）是主要为 I 型和 II 型光型或具有特定遗传因素并暴露于长期紫外线辐射的个体的皮肤区域的特征性皮肤病变。AK 可被视为原位鳞状细胞癌（SCC）的前驱病变，SCC 是一种非黑色素瘤皮肤癌（NMSC）。然而，仍然无法预测哪些 AK 病变会发展为 SCC。因此，建议及早治疗 AK。尽管越来越多的 AK 患者发展为 SCC，但迄今为止，对于 AK 仍没有明确的治疗策略建议。目前的治疗包括多种局部病灶定向或区域定向治疗，或两者联合治疗。最近，口服烟酰胺已显示可显著降低高危患者新发 NMSC 和 AK 的发生率。本研究旨在提供有关 AK 的最新相关信息，并深入了解当前和新的治疗选择。
